LUMA Vision Reports First-in-Human with 4D Cardiac Imaging Platform

LUMA Vision, a company specializing in cardiac navigation and visualization technology, reported successful first-in-human use and enrollment in its LUMINIZE clinical study using its Verafeye platform.

Verafeye is a four-dimensional catheter-based imaging system for interventional electrophysiology. According to LUMA Vision, its offers unprecedented, real-time visualization of the heart’s chambers. The system magnetically tracks navigation of third-party catheters.

Traditional imaging catheters offer only two-dimensional imaging, which can limit clinicians’ ability to see cardiac anatomy from all angles during procedures. Verafeye allows comprehensive, 360-degree visualization with enhanced depth and clarity, the company said. This enables the Verafeye Rapid Digital Anatomy (RDA) feature, which helps build CT-quality reconstructions of both atrial chambers in under a minute.

The first procedures were performed at the Mater Private Network, Dublin under the guidance of electrophysiologist Professor Gabor Széplaki.

“The VERAFEYE system provides a level of detail and real-time spatial context that is unmatched by traditional imaging methods,” Széplaki said. “This innovative technology represents a major leap forward in our ability to deliver precise and effective treatments for patients with complex heart conditions. VERAFEYE has the ability to provide all the navigation and imaging needed during today’s single shot procedures in one system.”

“We are thrilled by this milestone and the future possibilities it opens for cardiac care in areas such as cardiac arrhythmias, left atrial appendage closure and structural heart conditions,” added LUMA Vision CEO Fionn Lahart. “The development of VERAFEYE is a testament to our team’s commitment to pushing the boundaries of medical technology and with imminent market approval, we can equip clinicians with the tools they need to achieve better outcomes for patients worldwide.”

Read more: LUMA Vision Raises $22M in Series A3 Financing